Literature DB >> 20471516

Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma.

Alessandro Antonelli1, Regina Tardanico, Piera Balzarini, Nicola Arrighi, Laura Perucchini, Tiziano Zanotelli, Alberto Cozzoli, Danilo Zani, Sergio Cosciani Cunico, Claudio Simeone.   

Abstract

The purpose of this paper is to evaluate the clinical, pathologic, and cytogenetic features, as well as the disease-free survival in patients with papillary renal cell carcinoma (PRCC) subdivided into types 1 and 2, according to the definition given by Delahunt and Eble. The clinical, surgical, and follow-up data for the PRCC cases treated since 1995 were taken from an institutional database. The samples were revised by an experienced pathologist, who subdivided them into types 1 and 2. The data from the cases in which the tumor karyotype was available were analyzed. Out of 1,150 patients surgically treated for renal cancer, 132 cases of PRCC were detected (prevalence 11.5%), 57 with type 1 and 75 with type 2, followed for a mean period of 50 months. Tumor diameter, peri-renal tissues, as well as venous invasion, lymphnodal, and distant metastasis were highlighted to be distributed with a significant difference between the two groups, which indicated higher aggressiveness in type 2 cases. Survival analysis has showed a significantly higher-progression risk and a shorter disease-free survival in type 2 cases. An evaluable tumoral karyotype was obtained in 26 cases. An overlapping distribution was detected in chromosomes 7, 17, 12, 16, and 20, while some alterations in chromosomes 10, 5, 6, 11, 15, 18, 22, and 8 appeared as typical of type 2 cases. In conclusion, types 1 and 2 PRCC have different pathologic and cytogenetic features and a radically different biologic behavior - indolent in type 1 and aggressive in type 2. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20471516     DOI: 10.1016/j.cancergencyto.2010.02.013

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

Review 1.  Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Authors:  Maria Hernandez-Yanez; John V Heymach; Amado J Zurita
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Pediatric Renal Cell Carcinoma.

Authors:  Elizabeth J Perlman
Journal:  Surg Pathol Clin       Date:  2010-09-01

3.  Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney.

Authors:  Alexander Wolfe; Sheila M Dobin; Petr Grossmann; Michal Michal; Ludvik R Donner
Journal:  Virchows Arch       Date:  2011-08-07       Impact factor: 4.064

Review 4.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

5.  Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Authors:  Alcides Chaux; Luciana Schultz; Roula Albadine; Jessica Hicks; Jenny J Kim; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

6.  Spontaneous regression of biopsy proven primary renal cell carcinoma: A case study.

Authors:  Gurswinder Gary Jawanda; Darrel Drachenberg
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

7.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 8.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

9.  Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic Signature in Kidney Renal Papillary Cell Carcinoma.

Authors:  Ruyi He; Longyu Wang; Juan Li; Lixin Ma; Fei Wang; Yang Wang
Journal:  Front Cell Dev Biol       Date:  2020-12-03

10.  Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.

Authors:  Paari Murugan; Liwei Jia; Renzo G Dinatale; Melissa Assel; Nicole Benfante; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; Judy Sarungbam; S Joseph Sirintrapun; A Ari Hakimi; Paul Russo; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter
Journal:  Mod Pathol       Date:  2021-12-23       Impact factor: 8.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.